Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U....
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintai...
Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of...
Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compar...
